Weekly company factor report
CCLD Valuation, Quality and Momentum
CareCloud, Inc.
Current comparison
Latest company comparison
The scores rank this company against other measured companies in the selected market. Open each section to check the figures behind them.
Current factor profile
The completed price record is weak and does not support the other measures yet. Measured price variability is high and should be considered separately from the return figures.
Low valuation with strong finances
The company ranks at the 88th percentile for value and the 93th percentile for financial strength in this market.
Revenue growth with a moderate P/E
Revenue growth is 15% and the P/E ratio is 12 times earnings. Both figures should be checked against the company’s sector and reporting history.
Low valuation without price support
Value ranks 88/100, but price performance ranks only 16/100. The completed price record is not yet confirming the valuation case.
Capital returned is supported by cash flow
Shareholder yield is 13.8% and free-cash-flow yield is 16.3%. The cash-flow figure supports the reported distribution.
Borrowing contributes to the return on equity
Return on equity is 46% while debt to equity is 4.4. The return measure comes with greater balance-sheet risk.
Four main ranks
Company profile
Completed weekly snapshots
How the ranks have changed
Ready-made approaches
Which screens include this company
Passing a screen means the latest completed snapshot meets that screen’s published rules. It is not a recommendation.
Continue the research
Check the supporting evidence
Open the price record, technical position, market group or other company research that is available for CCLD.
Price against company results
Value
A higher value rank means the shares are cheaper on the combined definitions relative to this market. Negative earnings or cash flow need separate attention.
Current reading
The P/E ratio is 11.5 times earnings, which is low on the page’s valuation scale. Free-cash-flow yield is 16.3%, providing cash support for the valuation. The six-measure value score is 8.00000000/100, placing the company in the cheapest tenth of this market; lower is cheaper.
Value measures compared
Raw multiples and yields
P/E history
P/E is shown only when trailing earnings are positive.
Research path
How to test this valuation
A low valuation is a starting point. These checks show whether the earnings base, cash flow and completed price record support it.
Profitability, cash and balance sheet
Financial strength
The rank combines several company measures. The chart and figures below keep profitability, leverage and cash conversion visible separately.
Current reading
Return on equity is 46%. Debt to equity is 4.39; leverage contributes to both returns and balance-sheet risk.
Financial measures compared
Profitability and leverage
Completed returns and variability
Price performance and risk
Returns show direction; volatility and drawdown show how uneven the path has been. Both are based on completed prices.
Current reading
The 12-month return excluding the latest month is -28%, showing a negative completed price record. Near-term vol (127%) is expanding vs long-term (57%) — risk is increasing.
Returns over several periods
Recent and one-year volatility
How long the current readings have persisted
| Measure | Current | Current run | Direction |
|---|---|---|---|
| OS Composite | 0.860 | Unchanged for 16 snapshots | deteriorating |
| Value %ile | 0.880 | Unchanged for 16 snapshots | stable |
| Quality %ile | 0.930 | Unchanged for 16 snapshots | stable |
| Momentum %ile | 0.160 | Unchanged for 7 snapshots | deteriorating |
| F-Score | 5.000 | Unchanged for 0 snapshots | stable |
| Confidence | 0.970 | Unchanged for 16 snapshots | improving |
| Volatility | 0.566 | Unchanged for 16 snapshots | deteriorating |
Like-for-like context
Sector comparison
The company is compared with measured companies in Healthcare for the same completed factor week.
Company against sector
Valuation distance from sector
| Company | Combined | Value | Financial strength | Price performance |
|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals Inc | 99.0 | 95.0 | 97.0 | 98.0 |
| NUTX Nutex Health Inc | 99.0 | 92.0 | 98.0 | 96.0 |
| CGEN Compugen | 98.0 | 82.0 | 96.0 | 95.0 |
| HRMY Harmony Biosciences Holdings | 97.0 | 87.0 | 98.0 | 81.0 |
| INVA Innoviva Inc | 97.0 | 94.0 | 90.0 | 73.0 |
| RIGL Rigel Pharmaceuticals Inc | 97.0 | 85.0 | 95.0 | 86.0 |
| HCSG Healthcare Services Group Inc | 97.0 | 86.0 | 86.0 | 88.0 |
| JAZZ Jazz Pharmaceuticals PLC | 97.0 | 77.0 | 96.0 | 96.0 |
Reported company accounts
Company figures
Quarterly and annual figures are kept separate. The dates below show the latest accepted reporting periods.
Quarterly figures
Revenue
Net income
Free cash flow
Net margin
Operating income
Operating cash flow
Capital expenditure
Equity and liabilities
Annual figures
Revenue
Net income
Free cash flow
Net margin
Operating income
Operating cash flow
Capital expenditure
Equity and liabilities
Definitions and source checks
Measures and data
Each figure is shown with its plain definition. Percentile ranks compare the company with the selected market for the same completed week.
Value measures · Price compared with earnings, sales, assets and cash flow
Financial strength · Profitability, cash conversion and balance-sheet measures
Price performance · Completed price returns over several periods
Growth and stability · Revenue, earnings history and capital returned to shareholders
Combined value measures · Several valuation measures ranked together; 1 is cheapest
Capital use and company classification · Funding, distributions and company-size classifications
Company research path · week ending 18 Sep 2026
Company and valuation evidence are ahead of the price record
The company and valuation checks pass; completed price support is still building.
The path reads company results, valuation, completed price evidence and risk in that order. A later strength does not cancel an earlier weakness.
- ✓ Data readyPassed · 100/100 Published factors, company figures and completed prices are available.
- ✓ Company recordPassed · 79/100 Checks profitability, cash support, balance-sheet measures and their direction.
- ✓ Relative valuePassed · 88/100 Checks whether the current valuation compares well with the selected market.
- 4 Market supportNeeds more evidence · 33/100 Checks completed price performance, relative strength, trend and buying pressure.
- 5 Setup and riskNot reached · 18/100 Checks whether the price structure is usable without ignoring volatility or drawdown.
- 6 Full reviewNot reached Open the supporting company, market and risk research before making a decision.
Evidence used now
What moves the research path
Each block opens the report section containing the figures behind the score.
- Financial-strength rank 93/100
- F-Score 5/9
- 5 usable annual periods
- Value rank 88/100
- P/E 11.5×
- Free-cash-flow yield +16.3%
- Price-performance rank 16/100
- Six-month return -36.7%
- Relative strength +0.6
- Stage 4 · Declining
- Stage 4 · Declining
- Price at -37.8% of its 52-week high
- Completed price structure and risk combined
- One-year volatility 56.6%
- Recent volatility 127.0%
- 12-month drawdown -41.3%
Completed factor weeks
How the evidence has moved
All four lines are higher-is-better market ranks on the same 0–100 scale.
What the current evidence supports
- Company record scores 79/100.
- Relative value scores 88/100.
What still needs attention
- Market support scores 33/100.
- Setup scores 18/100.
- Risk check scores 15/100.
Next check
Wait for broader completed price, trend and relative-strength confirmation.
This path uses completed records and is recalculated with each published factor week. It is a research sequence, not a trade instruction.
Supporting Sharemaestro research
Continue with the available evidence
Only research pages with data for CCLD are shown.